美多巴联合恩他卡朋治疗帕金森病的临床研究  

Clinicalstudy of madopar combined with entacapone in the treatment of Parkinson's disease

作　　者：李爱美 邢红霞[2] LI Aimei;XING Hongxia(Department of Neurology,Third People’s Hospital of Sanmenxia,Sanmenxia 472143,China;Department of Neurology,First Affiliated Hospital of Xinxiang Medical University,Hena Key Laboratory of Neural Regeneration,Xinxiang 453100,China)

机构地区：[1]三门峡第三人民医院神经内科,河南三门峡472143 [2]新乡医学院第一附属医院神经内科五病区,河南新乡453100

出　　处：《中国实用神经疾病杂志》2018年第13期1480-1484,共5页Chinese Journal of Practical Nervous Diseases

摘　　要：目的观察美多巴联合恩他卡朋治疗法对帕金森病的临床疗效。方法选取三门峡第三人民医院收治的80例帕金森病患者纳为研究对象,随机分为对照组与观察组各40例,对照组单纯给予美多巴治疗,观察组采取美多巴联合恩他卡朋治疗,对比2组治疗前与治疗12周后汉密顿抑郁量表(HAMD)评分、生活能力(ADL)评分、副作用(TESS)评分及疗效。结果治疗12周后,观察组HAMD评分(6.58±1.74)分与TESS评分(2.12±0.84)分,明显低于对照组(11.43±2.86)分、(4.75±1.37)分,且ADL评分为(88.25±7.26)分,明显高于对照组(70.54±7.05)分(P<0.05);观察组治疗总有效率为95.00%,显著高于对照组的75.00%(P<0.05)。结论美多巴联合恩他卡朋治疗帕金森病,能有效改善患者抑郁程度,提高其生活能力,改善不良反应情况,获得显著疗效。Objective To study on clinical efficacy of madopar and entacapone in treatment of Parkinson's disease.Methods 80 cases of patients with Parkinson's disease treated in Third People’s Hospital of Sanmenxia were selected for the study and randomly divided into the control group and the observation group with 40 cases in each group.The control group was purely given madopar,and the observation group was given madopar combined with entacapone.The Hamilton Depression Scale(HAMD)score and life ability score(ADL)and side effects(TESS)score and efficacy were compared between the 2 groups before treatment and 12 weeks after treatment.Results After 12 weeks of treatment,the scores of HAMD and TESS were(6.58±1.74)points and(2.12±0.84)points in the observation group were significantly lower than those in the the control group with(11.43±2.86)points and(4.75±1.37)points,and the ADL score with(88.25±0.26)points was significantly higher than that in the control group with(70.54±7.05)points(P<0.05).The total effective rate of the observation group was significantly higher than that in the control group(95.00%vs 75.00%)(P<0.05).Conclusion Madopar combined with entacapone treatment program can effectively improve the degree of depression,life ability and decrease adverse reactions with a significant efficacy in the treatment of Parkinson's disease patients.

关 键 词：美多巴 恩他卡朋 帕金森病 HAMD评分 ADL评分 TESS评分 

分 类 号：R742.5[医药卫生—神经病学与精神病学]